FRNM
AI MemoPost-earnings T+1Freenome
As of 2026-11-11/Post-earnings T+1/Confidence medium
Data freshness
AI Memo
As of 2026-11-11 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Action
—
Confidence
medium
Horizon
—
Key catalyst
Q3 earnings: distinguish milestone revenue from recurring sales • 2026-11-14
Base target: $11 / p=45% prob
Biggest risk
The $180 million approval-related recognition dominates Q3 revenue and does not establish recurring test demand. Q3 R&D expense was $68.4 million, and reimbursement, adoption and future readout outcomes remain execution risks. The older July 10-Q excerpt concerns the predecessor SPAC, so it should not be used as Freenome's current operating baseline. SEC earnings exhibit [#SEC-10Q-2026-07-15]
Invalidation
Break below $8 or thesis failure.
What would change my mind?
FDA-approved CRC screening, an Abbott-led launch, approximately $430 million in September-end cash and marketable securities, and scheduled pipeline readouts provide meaningful opportunities. BTIG reportedly maintained Buy and a $17 target after the call, not an upgraded target. SEC earnings exhibit BTIG coverage report
Research note
Recommendation
—
Confidence
medium
As of
2026-11-11
Base target
$11
p=45%
Bull target
$15
p=25%
Bear target
$8
p=30%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- December single-cancer readouts
- CRC commercialization and multi-cancer development
- FDA-approved CRC screening, an Abbott-led launch, approximately $430 million in September-end cash and marketable securities, and scheduled pipeline readouts provide meaningful opportunities.
BearKey bullets
- An apparently favorable first reaction may reverse once investors distinguish milestone revenue from recurring sales.
- CRC adoption depends on commercial execution, payer coverage and testing volume.
- Clinical readouts and later regulatory steps may disappoint or slip.
WatchKey bullets
- Q3 earnings: distinguish milestone revenue from recurring sales
Summary
High-level snapshot
Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
Post-earnings T+1
Base case: $11 (p=45%)
Target spread vs base: +43% / -29%
Scenario probabilities
Bull Target: $15 (p=25%)Base Target: $11 (p=45%)Bear Target: $8 (p=30%)
Commentary
A contemporaneous report put the shares at $11.47, up 6.5% after hours from the November 10 close of $10.77; a November 11 regular-session closing reaction was not available. Investing.com earnings coverage BTIG reportedly reiterated—not raised—its $17 target. No dependable revenue/EPS consensus, broader estimate-revision series, options, short-interest, employee or social measures were supplied; zeros in those sentiment fields mean unavailable, not neutral readings. The deterministic prior is negative over 5–120 days, warranting caution despite strong primary confirmation of the release.
As of 2026-11-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
FDA-approved CRC screening, an Abbott-led launch, approximately $430 million in September-end cash and marketable securities, and scheduled pipeline readouts provide meaningful opportunities. BTIG reportedly maintained Buy and a $17 target after the call, not an upgraded target. SEC earnings exhibit BTIG coverage report
Bear Case
The $180 million approval-related recognition dominates Q3 revenue and does not establish recurring test demand. Q3 R&D expense was $68.4 million, and reimbursement, adoption and future readout outcomes remain execution risks. The older July 10-Q excerpt concerns the predecessor SPAC, so it should not be used as Freenome's current operating baseline. SEC earnings exhibit [#SEC-10Q-2026-07-15]
Drivers
Scannable catalysts and supporting factors
- December single-cancer readouts
- CRC commercialization and multi-cancer development
Scenarios
Bull Target (Scenario probability)
$15 / p=25% prob
Base Target (Scenario probability)
$11 / p=45% prob
Bear Target (Scenario probability)
$8 / p=30% prob
Analysis 2026-11-11 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
0.00
Social Sentiment (7d)
0.00
Events
Other notable items detected
- EVENT2026-11-14Q3 earnings: distinguish milestone revenue from recurring salesFreenome reported Q3 revenue of $183.5 million and diluted EPS of $0.58, but $180 million of revenue was recognized following SimpleScreen CRC approval under its collaboration agreement. Full-year revenue guidance is $192 million–$194 million. The immediate question is whether the Abbott-led launch produces repeatable testing revenue; a consensus-based earnings surprise was unavailable. [#8-K-2026-11-10] [#SEC-8K-2026-11-10] SEC earnings exhibitProb 100.00% • Move -3.00% • Priced-in 45.00%
Short-term Catalysts
Next few weeks
- December single-cancer readouts2026-12-31Management anticipates two additional single-cancer readouts in December. Their clinical performance and development implications, rather than the milestone-driven Q3 profit, could alter the pipeline thesis. The precise readout dates and outcomes are unknown. [#SEC-8K-2026-11-10] SEC earnings exhibitProb 70% • Move 8% • Priced-in 35%
Long-term Catalysts
Months to a year
- CRC commercialization and multi-cancer development2027-06-30SimpleScreen CRC launched in the U.S. through Abbott on September 30; Freenome also anticipates its first asymptomatic multi-cancer detection readout in mid-2027. Adoption, reimbursement and clinical validation remain unproven in the supplied evidence. [#SEC-8K-2026-11-10] SEC earnings exhibitProb 55% • Move 15% • Priced-in 30%
Risks
- An apparently favorable first reaction may reverse once investors distinguish milestone revenue from recurring sales.
- CRC adoption depends on commercial execution, payer coverage and testing volume.
- Clinical readouts and later regulatory steps may disappoint or slip.
- Q3 R&D expense of $68.4 million and uncertain future cash use create runway and financing risk despite September-end liquidity.
- Q3 profitability was heavily dependent on approval-triggered collaboration revenue; repeatable testing economics are not yet demonstrated.
Peers
| Symbol | Summary |
|---|---|
| GH | Guardant Health's Shield is a more direct blood-based colorectal-screening comparator than the packet's broad biopharma candidates. Differences in scale, reimbursement and commercial maturity limit valuation read-across. Guardant investor release |
| GRAL | GRAIL's Galleri provides a multi-cancer blood-test development comparator, but its regulatory stage and product scope differ from Freenome's approved CRC test. GRAIL Q3 release |
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-11-11